ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Detection of NRG1 Gene Fusions in Solid Tumors.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 227 citations in OpenAlex.
- CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (JCO precision oncology · 2025Trial
- Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies-a narrative review.Translational lung cancer research · 2026Review
- Cost-effectiveness analysis of molecular reflex testing-based targeted therapy in non-small cell lung cancer from a German healthcare payer perspective using a decision tree model.Cost effectiveness and resource allocation : C/E · 2026Article
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program.The oncologist · 2026Article
- Hypoxia‑induced exosomal CAMTA1 promotes radio‑resistance in MDA‑MB‑231 cells by regulating NRG1 to mediate M2 macrophage polarization.International journal of oncology · 2026Article
- NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.Journal of the National Cancer Institute · 2026Article
- Structure, mechanism and clinical relevance of NRG1 fusions in cancer.Journal of biomedical science · 2026Review
- Analysis of clinical and genomic features in a Chinese cohort withTranslational lung cancer research · 2026Article
- DIP2B as a Prognostic Biomarker and Immunotherapy Target: Insights from Pan-Cancer Analysis.Applied biochemistry and biotechnology · 2026Article
- Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.European journal of medical research · 2026Article
- NRG1 Suppresses NLRP3 Inflammasome Activation and Endothelial-Mesenchymal Transition in Cerebral Ischemia-Reperfusion Injury: Association with the AKT/NF-κB Pathway.Journal of inflammation research · 2026Article
- Whole-genome landscapes of 1,364 breast cancers.Nature · 2026Article
- Machine learning-based survival prediction in colorectal cancer combining clinical and biological features.Oncotarget · 2025Article
- Review
- Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors.Cancer research communications · 2025Article
- Development and validation of a machine learning-based prognostic model using mitochondrial dysfunction-related genes for colorectal cancer patients.Translational cancer research · 2025Article
- Fifty years of monoclonals: the past, present and future of antibody therapeutics.Nature reviews. Immunology · 2025Article
- Review
- Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors.NPJ precision oncology · 2025Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byDetection of2019
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
purposeEXPERIMENTAL
designTumor specimens submitted for molecular profiling at a Clinical Laboratory Improvement Amendments (CLIA)-certified genomics laboratory and that underwent fusion testing by anchored multiplex PCR for targeted RNA sequencing were retrospectively identified. The overall and tumor-specific incidence was noted, as was the specific fusion partner.
resultsOut of 21,858 tumor specimens profiled from September 2015 to December 2018, 41 cases (0.2%) harbored an
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.